BPC-157 Peptide: Status, Evidence and Sellers

BPC-157 is a synthetic 15-amino-acid peptide taken from a sequence found in human gastric juice. Researchers studying how the stomach protects its own lining identified it in the 1990s [1]. What drew early attention was its apparent stability in stomach acid and what it appeared to do to healing in rats. Today it circulates mainly in recovery, biohacking and sports circles, on claims about tendon, gut and soft-tissue repair.

The evidence behind those claims is almost entirely preclinical: cells and rats, not people. Not one randomized controlled trial in humans has been completed and published for any indication. It is not FDA-approved and not on the list of bulk substances pharmacies may compound with. Since October 28, 2026, though, an interim HHS policy says HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it under conditions [8]. Until then it moved almost entirely as an unregulated research chemical, and much of it still does.

The sections below cover what the published literature supports, with animal-only findings labeled as such. The enthusiasm on recovery forums is anecdote, which is a different kind of thing from evidence, not a weaker grade of it.

In animal models the proposed route runs through the nitric oxide system and through angiogenesis, the growth of new blood vessels into damaged tissue [4]. Interaction with VEGF pathways appears to be involved, along with some effect on nitric oxide synthase, which may account for part of the wound-healing signal seen in rats. In the gut, it has been studied for protecting the intestinal lining against damage from NSAIDs and other insults, apparently by holding the mucosal barrier together and damping local inflammation [2] [3].

For the musculoskeletal uses that drive most of the marketing, animal data suggest it may speed fibroblast proliferation and remodeling where tendon meets bone in rat injury models [5]. The molecular pathway is not fully characterized, and the distance between rat pharmacology and a human therapeutic effect is wide and entirely unvalidated [6].

Almost all of it comes from animals, and a striking share from one place. The literature originates largely with a single group at the University of Zagreb, which has run rat-model studies for three decades across protection of the stomach lining [1] [2], repair of tendon and ligament [5], and how blood vessels behave [4]. Those studies are internally consistent and mechanistically interesting. They remain animal data.

A 2026 translational review in Pharmaceutics calls it an investigational peptide therapeutic and identifies the thing that matters most: no completed Phase I or Phase II human trial exists at all, which is a fundamental barrier rather than a gap waiting to be filled [6]. The review also catalogs formulation and biopharmaceutical problems that complicate getting to human studies in the first place.

An independent 2026 review in Sports Medicine assessed approved and unapproved peptides in musculoskeletal injury and athletic performance. It concluded the human evidence for this one is insufficient to support recommending it to patients or athletes [7].

Evidence grade C, preclinical only. Every online claim about tendon repair, gut healing or recovery in people is an extrapolation from rodents. That extrapolation has had three decades to be tested and has not been, which itself says something about how hard the translation is turning out to be.

There is no established human dose, because there are no completed human trials to establish one. No dose is approved for any use. Rodent studies dosed by body weight, under the skin or into the stomach, and those amounts do not convert into a human dose. Amounts quoted by vendors and forums have no tested basis, and this page does not repeat them.

Oral versions are widely sold. The argument for them is that the peptide holds up in stomach acid, which might support some absorption, but there are no human absorption data to check that against. The October 28, 2026 HHS policy covers compounded BPC-157 acetate given by subcutaneous or intramuscular injection, by mouth or on the skin. For an oral product the pharmacy is expected to document that the formulation reaches adequate levels in the human body, which no published study has yet shown [8]. The policy sets routes and quality conditions, not doses. Research-chemical sellers, who label their vials as not meant for people, are outside it.

Nobody knows the long-term safety profile in humans. Rat studies have not turned up outright organ toxicity at the doses tested, but rodent safety is not a dependable proxy for human safety with complex peptides. The 2026 Sports Medicine review made the point that unapproved peptides carry risk from the supply chain itself: unregulated manufacturing, unknown purity, and no pharmacovigilance data [7]. What arrives in a vial bought online may be the wrong dose, may be impure, or may be a different sequence than the label claims.

BPC-157 is not on the 503A Bulks List, the list of bulk drug substances a pharmacy may compound with, and it is neither a USP monograph substance nor a component of any approved drug. FDA's May 2026 briefing document for its Pharmacy Compounding Advisory Committee recommended against adding it, citing inconsistent chemical characterization, missing data on peptide impurities and aggregates, and the risk that an injectable form provokes an immune response. The committee voted in favor anyway, and on October 28, 2026 HHS issued an interim policy under which HHS does not intend to take enforcement action against a licensed pharmacy or physician compounding BPC-157 acetate through section 503A on its conditions. Those conditions include a single active ingredient, bulk peptide from an FDA-registered facility with a certificate of analysis, a patient-specific prescription, and a duty to tell FDA, through MedWatch, about serious harm or defective product [8]. The policy approves nothing, lasts until a final rule decides the listing, and can be revisited if a safety signal appears. It is approved for no human indication. Bought as a research chemical, its use is unregulated, and even a compounded prescription carries risks nobody can yet quantify. That is because the human safety data needed to quantify them does not exist, which is different from knowing the risks are small.